Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 13, 2025
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on November 11, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. Key metrics provided include:
- Share Repurchase Programme (Nov 11, 2024 – Feb 3, 2025): Authorized up to DKK 3,136,206,122.30.
- Transactions since Dec 20, 2024: 682,392 B shares repurchased for a total value of DKK 413,977,029.
- Accumulated Repurchases (Current Programme): 2,990,267 B shares for DKK 2,172,308,952.
- Total Repurchases (Since Feb 6, 2024): 23,193,366 B shares at an average price of DKK 820.76, totaling DKK 19,036,102,830.
- Treasury Shares: 24,337,924 B shares owned, representing 0.5% of share capital.
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing details the execution of share buybacks under the Safe Harbour Rules. Since the last announcement on December 20, 2024, the company has actively repurchased shares on six trading days in January 2025. The average purchase price for these recent transactions ranged between DKK 604.45 and DKK 636.79. The total value repurchased under the current 12-month programme has reached approximately DKK 19.0 billion, nearing the DKK 20 billion authorization limit.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during the 12-month period beginning February 6, 2024. As of January 10, 2025, the company has utilized approximately 95% of this authorized amount.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies. It notes that transaction details are published on the company website and that the programme is conducted in accordance with EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization amount under the DKK 20 billion share repurchase programme (approx. DKK 964 million remaining).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average repurchase price (approx. DKK 620-630).
- Review the company's full annual report (Form 20-F) for comprehensive revenue, profit, and liquidity data not included in this 6-K.
- Monitor the company website for the final transaction details once the 12-month repurchase period concludes.